Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Autoimmune Diseases Research Model Developed to Clarify Antibody Mechanisms

By BiotechDaily International staff writers
Posted on 21 Jul 2013
Canadian scientists have devised a unique research model for the study of autoimmune diseases. The Montréal scientists are the first to find an approach to better understand two significant processes that enhance the quality of antibodies.

This study, conducted by researchers from the l'Institut de Recherches Cliniques de Montréal (IRCM; QB, Canada), led by Dr. Javier M. Di Noia in the immunity and viral infections research division, was published in the June 15, 2013, issue of the Journal of Immunology.

Dr. Di Noia’s team is evaluating B cells, a group of white blood cells known as lymphocytes whose major task is to make antibodies to fight against antigens. “Our project focused on two mechanisms that produce this wide variety of antibodies,” said Dr. Di Noia, director of the mechanisms of genetic diversity research unit at the IRCM. “Because both processes are initiated by the same enzyme known as AID [activation-induced deaminase], it had previously been very difficult to study them separately. We were able to identify, for the first time, a mouse model in which the mechanisms could be analyzed independently during an acute immune response.”

The two processes being studied are known as class switching and affinity maturation. Class switching is the mechanism that allows a B cell to generate diverse classes of antibodies, so that a single antibody can be used by several different parts of the immune system. Affinity maturation, on the other hand, is the process by which B cells produce antibodies with increasingly stronger bonds to antigens during an immune response.

“Since eliminating AID would in turn completely eliminate affinity maturation and class switching, we focused on an enzyme called UNG, which is also involved in both processes,” added Astrid Zahn, research associate in Dr. Di Noia’s laboratory and first author of the study. “When we analyzed mice lacking the UNG [uracil-DNA glycosylase] gene, we found that affinity maturation was normal but class switching was strongly reduced during acute immune responses, such as the response to immunization and against a viral infection.”

“While over 100 AID-deficient patients have been identified, it is striking that only a handful of patients are known to be UNG-deficient,” explained Dr. Zahn. “Our study, which shows that chronic antibody responses [those to environmental antigens] remain nearly normal without UNG, can explain why most UNG-deficient individuals are not detected among immunodeficient patients. Nevertheless, because we also found that acute antibody responses were significantly affected, we suspect that UNG-deficient people will, for example, respond very poorly to vaccination. In addition, as this work was conducted as part of a larger ongoing investigation of the complex relationship between AID and UNG, we believe that UNG might possibly act as a tumor-suppressor in B-cell lymphomas.”

“Until now, it was difficult to study the relative importance of class switching and affinity maturation, and the impact of these two mechanisms on immune responses,” concluded Dr. Di Noia. “Our study provides a novel model to study the contribution of these mechanisms in certain autoimmune diseases such as lupus and rheumatoid arthritis, or some infections like influenza.”

Related Links:

l'Institut de Recherches Cliniques de Montréal



Channels

Genomics/Proteomics

view channel
Image: Transmission electron micrograph of norovirus particles in feces (Photo courtesy of Wikimedia Commons).

Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.